CeriBell (NASDAQ:CBLL) CEO Xingjuan Chao Sells 20,846 Shares

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 20,846 shares of the company’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $25.03, for a total transaction of $521,775.38. Following the sale, the chief executive officer directly owned 746,345 shares of the company’s stock, valued at approximately $18,681,015.35. This represents a 2.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Xingjuan Chao also recently made the following trade(s):

• On Wednesday, September 2nd, Xingjuan Chao sold 39,540 shares of CeriBell stock. The shares were sold at an average price of $24.61, for a total value of $973,079.40.
• On Friday, August 21st, Xingjuan Chao sold 6,068 shares of CeriBell stock. The stock was sold at an average price of $24.02, for a total value of $145,753.36.
• On Wednesday, August 19th, Xingjuan Chao sold 31,415 shares of CeriBell stock. The stock was sold at an average price of $25.03, for a total value of $786,317.45.
• On Tuesday, August 18th, Xingjuan Chao sold 2,199 shares of CeriBell stock. The stock was sold at an average price of $25.00, for a total value of $54,975.00.
• On Tuesday, July 7th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $19.90, for a total value of $776,100.00.

CeriBell Trading Up 2.0%

Shares of CBLL stock traded up $0.50 on Thursday, hitting $25.00. 734,947 shares of the stock traded hands, compared to its average volume of 280,012. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.79 and a current ratio of 9.18. CeriBell, Inc. has a twelve month low of $10.85 and a twelve month high of $25.63. The firm’s 50-day moving average price is $21.51 and its two-hundred day moving average price is $19.79. The stock has a market capitalization of $959.50 million, a PE ratio of -14.20 and a beta of 0.95.

CeriBell (NASDAQ:CBLL) last issued its earnings results on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%.The firm had revenue of $28.10 million for the quarter, compared to analysts’ expectations of $27.28 million. As a group, analysts anticipate that CeriBell, Inc. will post -1.96 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on CBLL shares. Weiss Ratings raised CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. Canaccord Genuity Group raised their price objective on CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. BTIG Research restated a “buy” rating and issued a $30.00 price objective on shares of CeriBell in a report on Friday, September 11th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $29.00 target price on shares of CeriBell in a research note on Thursday, September 3rd. Finally, Barclays upgraded shares of CeriBell to a “neutral” rating in a report on Tuesday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, CeriBell has a consensus rating of “Moderate Buy” and a consensus price target of $24.40.

Hedge Funds Weigh In On CeriBell

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Squarepoint Ops LLC acquired a new position in CeriBell in the 2nd quarter valued at about $638,000. Wellington Management Group LLP boosted its stake in shares of CeriBell by 5.5% in the second quarter. Wellington Management Group LLP now owns 87,698 shares of the company’s stock valued at $1,706,000 after purchasing an additional 4,572 shares during the period. Formula Growth Ltd. acquired a new position in shares of CeriBell in the second quarter valued at approximately $603,000. Bank of America Corp DE purchased a new stake in CeriBell during the 2nd quarter worth approximately $4,619,000. Finally, PDT Partners LLC purchased a new position in CeriBell in the 2nd quarter valued at approximately $1,026,000.

About CeriBell

Ceribell, Inc (NASDAQ: CBLL) is a medical technology company focused on improving the detection and management of seizures and other neurological conditions in hospital settings. Its products are designed to make electroencephalography (EEG) more accessible at the point of care, particularly in emergency departments, intensive care units and other settings where conventional EEG testing may be delayed or difficult to obtain.

The company’s primary offering is the Ceribell Rapid Response EEG system, which combines a portable EEG recorder, a simplified electrode headband and software for acquiring and reviewing brain-wave data.